A randomised multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children

Indian J Pediatr. 1994 Nov-Dec;61(6):689-93. doi: 10.1007/BF02751980.

Abstract

A randomised control multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children is reported. One hundred and fifty children of either sex (age range: 2-10 years) were randomised to receive either a single dose of 400 mg of albendazole suspension, or 22.5 mg/kg/day of metronidazole in 3 divided doses for 5 consecutive days. At the end of therapy, majority of children in both treatment groups were symptom free. Two days after completion of therapy, 97% of children in both treatment groups were giardia free in the stools. Side effects were noted in 3 children in the albendazole group, and in 20 children in the metronidazole group. We conclude that albendazole suspension is as effective as metronidazole in the treatment of giardial infection in children. It is safe and has fewer side effects as compared to metronidazole.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Albendazole / adverse effects
  • Albendazole / therapeutic use*
  • Animals
  • Child
  • Child, Preschool
  • Feces / parasitology
  • Female
  • Giardia / isolation & purification
  • Giardiasis / diagnosis
  • Giardiasis / therapy*
  • Humans
  • Male
  • Metronidazole / adverse effects
  • Metronidazole / therapeutic use*

Substances

  • Metronidazole
  • Albendazole